Reportlinker Adds Small Molecule Kinase Inhibit...(rd line NSCLC in the US and Rest of Worl...)

Table 16: Canadian Healthcare Market (2007): Breakdown of Total Payments Made by Private and Public Insurers Towards Take Home Cancer Drugs (THCDs) by Select Drug Brands - Gleevec, Tarceva, Sutent, Nexavar, Sprycel, and Iressa (In US$ million) (includes corresponding Graph/Chart) II-21

Table 17: Canadian Healthcare Market (2007&2008): Percentage Share Breakdown of Patient Claims Made for Small Molecule Kinase Inhibitors by Select Drug Brands - Gleevec, Tarceva, Sprycel, and Tasigna (includes corresponding Graph/Chart) II-21

Outlook II-22

Future Directions: The Shape of Things to Come II-22

Spotlight On HER3 Kinase Inhibitors to Overcome Resistance to EGFR & HER2 Kinase Inhibitors II-22

Ras-Raf-MEK-ERK: A New Kinase Pathway to Achieve Cell Cycle Arrest II-22

Key Small Molecule pKis Under Different Stages of Clinical Trials II-23

Pharmaceutical Industry: Review of the Present Scenario II-25

Developing Countries Hold the Key to Future Growth II-25

Table 18: World Pharmaceutical Industry (2007): BRIC Nations (Brazil, Russia, India and China), & United States Ranked by Percentage Growth (includes corresponding Graph/Chart) II-26

Consolidation Gets Underway II-26

Landmark Deals Announced or Completed by Pharma and Biotech Companies Engaged in Developing Kinase Inhibitor Drugs, During the Year 2008 & 2009 II-27

Impact of the Recession: An Unequivocal ReviewII-27

Recession Brings Drug Development Efforts Under Siege II-27

Biotech Bankruptcies: Casualties On the Rise II-28

2. KINASE INHIBITOR DRUGS: AN OVERVIEW II-29

Small Molecule Kinase Inhibitors: A Definition II-29

Imatinib (Gleevec(R), Glivec(R) - Novartis) II-29

Approvals II-29

Approvals Pending II-29

Erlotinib (T
'/>"/>